Learn how decades of #immunotherapy research is resulting in new cancer therapies: http://t.co/xMDUCNNN37 http://t.co/bAkC5xMmtH
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
Krishan Maggon 's curator insight,
August 23, 2014 8:53 PM
Cancer Immunol Res. 2014 Aug;2(8):714-9. doi: 10.1158/2326-6066.CIR-14-0119.Cancer Immunotherapy Highlights from the 2014 ASCO Meeting.Harshman LC1, Drake CG2, Wargo JA3, Sharma P4, Bhardwaj N5. |
Krishan Maggon 's curator insight,
April 3, 2015 10:02 AM
The safety and activity of TG4010 have been evaluated in Phase 1 and 2 studies in several types of solid tumors. TG4010 is currently in late-stage clinical development for the treatment of advanced MUC-1 positive NSCLC.
In 2014, Transgene reported results from the Phase 2b part of the Phase 2b/3 TIME trial evaluating TG4010 in combination with chemotherapy in patients with Stage IV NSCLC. The primary objective of the Phase 2b part of the trial was to validate a predictive biomarker for efficacy that was identified in an earlier Phase 2 trial (TG4010.09) in NSCLC. The results of both the Phase 2b part of the TIME trial and the TG4010.09 trial are discussed below.
The improvements in PFS and OS in this non-squamous population were even more notable in the so-called “low” TrPAL group of patients; the low TrPAL group is similar to the normal TrPAL group but with a slightly lower TrPAL cell threshold level corresponding to the 75% of patients with the lowest values. TG4010 was well tolerated, and the nature and incidence of adverse events in the TG4010 arm were consistent with previous Phase 2 clinical trials. The most frequent TG4010-related adverse events were mild to moderate injection site reactions. The Company is moving forward with preparations for the Phase 3 part of the TIME trial, which is planned to enroll only patients with non-squamous disease. Transgene is seeking a global development and commercialization partner for TG4010 and talks are ongoing with potential partners. |